Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein Receptor-Binding Domain (RBD) is a recombinant protein expressed in Mammalian cells.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the Spike Protein and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The B.1.617 variant was first identified in India. It contains the E484Q and L452R mutations and is therefore widely known as a "double mutation" variant. These mutations have been reported to increase binding to human ACE2 and reduce antibody neutralization of the virus, in comparison with other variants.
Research Articles on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (B.1.617 Variant)
||Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (B.1.617 Variant)
||Optimal dilutions/concentrations should be determined by the end user.
||> 90% (SDS-PAGE)
||Reconstitute in ddH2O to a concentration of 1 mg/ml.
||Store between -20 °C and -80 °C. Avoid repeated freeze/thaw cycles.
||Observed MW: 35 kDa
||C-terminal His tag
||Prior to lyophilization: PBS, pH 7.5.
||Shipped within 5-10 working days.
||This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.